Edition:
United States

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

58.99USD
21 Feb 2018
Change (% chg)

-- (--)
Prev Close
$58.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,779,821
52-wk High
$64.60
52-wk Low
$42.32

Select another date:

Fri, Feb 16 2018

BRIEF-Abbott Sets Quarterly Dividend Of $0.28/Share

* ABBOTT SETS QUARTERLY DIVIDEND OF $0.28PER SHARE Source text for Eikon: Further company coverage:

Deals of the day-Mergers and acquisitions

Jan 24 The following bids, mergers, acquisitions and disposals were reported by 2030 GMT on Wednesday:

Abbott to take a pause after deal spree

Abbott Laboratories said on Wednesday it was not looking at acquisitions this year as the healthcare company looks to ease its debt burden after a spree of deals last year.

UPDATE 3-Abbott to take a pause after deal spree

* Successful integration of recent deals an "execution story"- analyst

BRIEF-Abbott Posts Q4 Adj. EPS $0.74 From Continuing Operations

* SEES Q1 2018 ADJUSTED EARNINGS PER SHARE $0.57 TO $0.59 FROM CONTINUING OPERATIONS EXCLUDING ITEMS

Abbott posts quarterly loss on $1.4 bln tax charge

Jan 24 Abbott Laboratories reported fourth-quarter loss on Wednesday compared with a year-ago profit, as the diversified healthcare company took a $1.4 billion charge due to the recent U.S. tax overhaul. It posted a net loss of $828 million, or 48 cents per share, in the quarter ended Dec. 31 compared with a profit of $798 million, or 53 cents per share, a year earlier.

Abbott Laboratories expected to post earnings of 73 cents  a share - summary

* Abbott Laboratories is expected to show a rise in quarterly revenue when it reports results on January 24.

BRIEF-Biogaia signs deal with Abbott to launch probiotic in China

* SAYS HAS SIGNED AN EXCLUSIVE AGREEMENT WITH ABBOTT FOR RIGHTS TO COMMERCIALIZE BIOGAIA PROTECTIS TABS IN CHINA

CMS to cover Abbott's glucose monitoring device

Abbott Laboratories said on Thursday its newly launched glucose monitoring device would be covered by the Centers for Medicare & Medicaid Services, expanding its usage to millions of diabetes patients in the United States.

CMS to cover Abbott's glucose monitoring device

Jan 4 Abbott Laboratories said on Thursday its newly launched glucose monitoring device would be covered by the Centers for Medicare & Medicaid Services, expanding its usage to millions of diabetes patients in the United States.

Select another date: